Collegium Pharmaceutical, Inc. COLL Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s retained earnings?
- Collegium Pharmaceutical, Inc. (COLL) reported retained earnings of -$86.63M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s retained earnings changed year-over-year?
- Collegium Pharmaceutical, Inc.'s retained earnings increased by 46.4% year-over-year, from -$161.58M to -$86.63M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s retained earnings has grown at a -21.2% compound annual growth rate (CAGR), from -$333.15M to -$101.13M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.